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Malaria is a leading public health problem in tropical and subtropical countries 
of the world. In 2019, there were an estimated 229 million malaria cases and 409, 
000 deaths due malaria in the world. The objective of this chapter is to discuss 
about the different Plasmodium parasites that cause human malaria. In addition, 
the chapter discusses about antimalarial drugs resistance. Human malaria is caused 
by five Plasmodium species, namely P. falciparum, P. malariae, P. vivax, P. ovale and 
P. knowlesi. In addition to these parasites, malaria in humans may also arise from 
zoonotic malaria parasites, which includes P. inui and P. cynomolgi. The plasmodium 
life cycle involves vertebrate host and a mosquito vector. The malaria parasites differ 
in their epidemiology, virulence and drug resistance pattern. P. falciparum is the 
deadliest malaria parasite that causes human malaria. P. falciparum accounted for 
nearly all malarial deaths in 2018. One of the major challenges to control malaria is 
the emergence and spread of antimalarial drug-resistant Plasmodium parasites. The 
P. vivax and P. falciparum have already developed resistance against convectional 
antimalarial drugs such as chloroquine, sulfadoxine-pyrimethamine, and atova-
quone. Chloroquine-resistance is connected with mutations in pfcr. Resistance to 
Sulfadoxine and pyrimethamine is associated with multiple mutations in pfdhps 
and pfdhfr genes. In response to the evolution of drug resistance Plasmodium 
parasites, artemisinin-based combination therapies (ACTs) have been used for the 
treatment of uncomplicated falciparum malaria since the beginning of 21th century. 
However, artemisinin resistant P. falciparum strains have been recently observed in 
different parts of the world, which indicates the possibility of the spread of arte-
misinin resistance to all over the world. Therefore, novel antimalarial drugs have to 
be searched so as to replace the ACTs if Plasmodium parasites develop resistance to 
ACTs in the future.
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1. Introduction
Malaria is a leading public health problem in tropical and subtropical countries 
of the world. The disease is caused by Plasmodium parasites that are transmitted by 
the bites of infected female Anopheles mosquitoes. In 2019, there were an esti-
mated 229 million malaria cases and 409, 000 deaths due the disease in the world. 
Children aged under 5 years are the most vulnerable group, which accounted for 
67% of all malaria deaths occurred in 2019. Nearly 94% of all malaria cases in 2019 
occurred in Africa [1].
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In addition to its health burden, malaria has also placed a heavy economic 
burden in Africa. Since 2000, the average annual cost of case management alone has 
been estimated nearly USD 300 million in Africa [2]. One of the main challenges of 
controlling malaria is the evolution of drug resistant strains of Plasmodium species 
against available antimalarial drugs [3–5]. In this chapter, antimalarial drugs resis-
tance has been discussed. Furthermore, the life cycle, clinical features and chemo-
therapy of the different species of human malaria parasites have been discussed.
2. Plasmodium species causing human malaria
2.1 Diversity of human malaria parasites
Malaria is caused by protozoan parasites that belongs to the genus Plasmodium. 
There are over 200 plasmodium species that have been proven to cause malaria. 
But human malaria is caused by only by five Plasmodium species, namely: - 
Plasmodium falciparum (P. falciparum); Plasmodium vivax (P. vivax); Plasmodium 
malariae (P. malariae), Plasmodium ovale (P. ovale) and Plasmodium knowlesi  
(P. knowlesi) [6]. While the first four plasmodium species (P. falciparum, P. vivax, 
P. malariae and P. ovale) naturally cause malaria only in humans, P. knowlesi causes 
zoonotic malaria in South East Asia, that is naturally maintained in macaque 
monkeys. The malaria parasites differ in their epidemiology, virulance and drug 
resistance pattern. Of the five human malaria parasites, P. vivax and P. falciparum 
pose the greatest threat. P. falciparum is the most dangerous malaria parasite that is 
responsible for high morbidity and mortality [7, 8]. P. falciparum is the most preva-
lent human malaria parasite in Africa, that accounted for 99.7% of the estimated 
malaria cases in 2018 [9].
Plasmodium parasites belong to the order Haemosporidia [10]. The different 
Plasmodium species have different host range. For example, the host range of  
P. relictum is so broad, that can infect more than 100 different species of birds, that 
belong to different orders and families [11]. Whereas, the host range of P. falci-
parum is so narrow that only infects humans [12]. In contrast to mammalian malaria 
parasites, that are only transmitted by are mosquitoes of the genus Anopheles, 
Plasmodium species that infect birds are transmitted by a wide variety of mosqui-
toes including Culex and Aedes [13].
2.2 The life cycle of malaria parasites
The life cycle of human malaria parasites is generally the same [14]. The plas-
modium life cycle involves two hosts (has two parts). In the first part, the parasite 
infects a vertebrate host such as human being and in the second part, the plasmodium 
parasite infects the mosquito vector.
The Plasmodium life cycle starts when sporozoites enter the blood of the 
vertebrate host following a bite by the mosquito vector [15]. Then, the sporozoites 
rapidly move to the liver and invade hepatocytes where they multiply asexually by 
a process called schizogony (exo-erythrocytic schizogony) and produce merozoites 
[16, 17]. The merozoites are released back into the blood and infect erythrocytes 
[18]. In only P. ovale and P. vivax infection, some of the merozoites in the liver may 
differentiate into a dormant stage (hypnozoite), which may recure again (cause 
relapse by invading blood stream) after some time in the future unless treated with 
primaquine. In the infected erythrocyte, each merozoite multiplies by schizogony 
(erythrocytic schizogony) to produce between 8 and 64 new merozoites, depending 
on the species of the plasmodium parasite [19]. The newly produced merozoites are 
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released back to the blood, and continues its intraerythrocytic propagation cycle 
every 72 (P. malariae) hours; every 24 hours (P. knowlesi), and every 48 hours (P. 
falciparum, P. ovale, P. vivax). Some of the merozoites differentiate into male and 
female gametocytes for sexual reproduction [20, 21].
The second part of the plasmodium life cycle starts when the insect vector bites 
infected vertebrate host (such as infected person) and the insect ingests the blood 
containing gametocytes. The gametocyte completes its development in the lumen of 
the mosquito midgut and the male and the female gametes fuse to produce a zygote 
[22], which is the only stage with diploid chromosome (genome) [23].
Following fertilization, the zygote undergoes meiosis and differentiates into 
ookinete (motile form) that has a haploid genome [24]. Then ookinete penetrates 
the wall of the midgut of the mosquito and forms an oocyst [25]. In the oocyst, 
mitosis take place repeatedly, and numerous sporozoites are produced by sporogony 
[26, 27]. When the oocyst matures, it ruptures and releases sporozoites into the hae-
molymph. Then, the sporozoites migrate to the salivary glands, where they mature 
and acquire the capacity to infect vertebrate host cells [28]. This cycle (second part 
of the plasmodium parasite life cycle (from gametocytes to sporozoites) takes about 
10–18 days.
2.3 Plasmodium falciparum
P. falciparum is the deadliest Plasmodium species that causes human malaria 
[29]. According to the World Health Organization (WHO), P. falciparum accounted 
for nearly all malarial deaths (99.7%) in 2018, which caused an estimated 405,000 
deaths [9]. With the exception of Europe, P. falciparum is found in all continents of 
the world. Before 1970s, P. falciparum malaria was common in Europe. But interven-
tions which includes appropriate case management, insecticide spraying, and envi-
ronmental engineering since the early 20th century resulted in complete eradication 
in the 1970s [30]. Unlike other malaria endemic countries in which non-falciparum 
malaria predominates, over 75% of malaria cases were due to P. falciparum in Sub-
Saharan Africa [31], where 94% of malaria deaths occur [9].
The average incubation period of P. falciparum malaria is 11 days (ranging from 
9 to 30 days) [32], which is the shortest among Plasmodium species. The sign and 
symptoms of uncomplicated malaria include fever, headache, nausea, vomiting, and 
diarrhea. If left untreated, P. falciparum malaria usually develops to sever malaria, 
which may bring about death. Children with severe malaria frequently develop 
severe anemia and or respiratory distress [33]. Multi-organ failure is common in 
adults with sever malaria. Acute respiratory distress occurs in 5–25% of adults and 
up to 29% of pregnant women [34].
The WHO recommends Artemisinin-based combination therapies (ACTs) 
as first-line treatment for uncomplicated P. falciparum malaria. The ACTs that 
are recommended by the WHO for the treatment of uncomplicated P. falciparum 
malaria include Artemether/lumefantrine, dihydroartemisinin/piperaquine, 
artesunate/amodiaquine, artesunate/mefloquine, and artesunate/sulfadoxine-
pyrimethamine [35]. The choice of ACT that be used in different parts of the 
world is different, that depends on the level of resistance to the constituents in the 
ACT. In a condition when first line therapy fails, the following alternative antima-
larial drugs can be used as second-line treatment: - artesunate plus tetracycline 
or doxycycline or clindamycin, and quinine plus tetracycline or doxycycline or 
clindamycin which is given for seven days.
The recommended first-line treatment of uncomplicated P. falciparum malaria 
in pregnant women during the first trimester is quinine plus clindamycin for seven 
days [35]. The second line therapy for the treatment of uncomplicated P. falciparum 
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malaria in pregnant women is artesunate plus clindamycin for 7 days. Atovaquone/
proguanil, or artemether/lumefantrine or quinine plus doxycycline or clindamycin 
are recommended for treatment of malaria in travelers returning to non-malaria 
endemic countries [35]. The recommended treatment for sever P. falciparum 
malaria in adults is intravenous (IV) or intramuscular (IM) artesunate. Quinine is 
also recommended as an alternative treatment of sever P. falciparum malaria if par-
enteral artesunate is not available [35]. Whereas, artesunate (IV or IM), quinine (IV 
or IM), and artemether IM are recommended for treatment of sever P. falciparum 
malaria in children, especially in malaria-endemic areas of Africa [35].
2.4 Plasmodium vivax
P. vivax is the second important malaria parasite after P. falciparum, that causes 
significant morbidity. The parasite can cause severe disease and even death that is 
usually associated with splenomegaly [36, 37]. One of the important features that 
distinguishes P. vivax from P. falicparum is the occurrence of dormant stage in the 
liver (hypnozoites) that can be reactivated later in life.
The burden of P. vivax malaria differ from one region of the world to the other, 
which is mainly seen in central Asia (82%), the Americas (6%), Southeast Asia 
(9%), some parts of Africa (3%) [38, 39]. P. vivax has wider distribution than  
P. falciparum, which is associated with the dormant stage of P. vivax and the ability 
of P. vivax to survive and reproduce in the mosquito vector at lower temperatures 
and higher altitudes. In Africa, P. vivax is limited to parts of horn of Africa and 
Madagascar, unlike the other parts of Africa that is not affected by P. vivax infec-
tion due to the deficiency of Duffy antigen (which serves as receptor for the 
parasite) in the population [40]. It has been suggested that P. vivax originated 
in Africa. This is based on the fact that gorillas and wild chimpanzees in central 
Africa are naturally infected with plasmodium parasite that are closely related to 
the P. vivax that causes human malaria [41].
Usually, P. vivax causes mild disease, that causes fever, cough, abdominal pain 
and diarrhea. However, the parasite may cause serious conditions like respiratory 
distress. In pregnant women, P. vivax infection brings about low birth weight. In 
rare cases, complications might arise from P. vivax infection, which includes acute 
kidney failure, neurological abnormalities, hypoglycemia and low blood pressures, 
jaundice and coagulation defects [42]. Chloroquine is the drug of choice for the 
treatment of malaria that is caused by P. vivax [43]. However, in areas where the 
parasite has developed resistance for Chloroquine, such as Papua New Guinea, 
Korea, and India where chloroquine resistance has grown up to 20% resistance [44], 
chloroquine has been replaced by other drugs.
2.5 Plasmodium ovale
P. ovale is one of the five human malaria parasites. Unlike P. falciparum and 
P. vivax, P. ovale accounts very small proportion (5%) of the disease [45]. The 
species P. ovale is consisted of two subspecies, P. ovale curtisi and P. ovale wal-
likeri [46]. P. ovale is mainly found in Islands in western pacific and Sub-Saharan 
Africa [45, 47]. But the parasite also exists in Thailand [48], Vietnam [49] 
Guinea [50], Bangladesh [51], Cambodia [52] India, [53] and Myanmar [54]. The 
incubation period of P. ovale ranges from 12 to 20 days. The parasite causes very 
mild disease and it is less dangerous than P. falciparum. Like P. vivax, P. ovale 
has a dormant stage in the liver (hypnozoites) that can be reactivated later in 
life [45]. Chloroquine is the drug of choice for the treatment of malaria that is 
caused by P. ovale [55].
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2.6 Plasmodium malariae
P. malariae is one of the five human malaria parasites. It causes mild disease, 
which is therefore called benign malaria. P. malariae is found in the Amazon Basin 
of South America, sub-Saharan Africa, much of southeast Asia, Indonesia, and on 
many of the islands of the western Pacific [56]. The parasite causes a chronic infec-
tion that may sometimes last for a lifetime. Some of the major defining features of 
P. malariae include its longer (72-hour developmental cycle) (quartan periodicity) 
(compared with the 48-hour cycle of P. vivax and P. falciparum) and lower parasit-
emia compared to those in patients infected with P. falciparum or P. vivax [57, 58]. 
The signs and symptoms of P. malariae malaria include fever, chills and nausea and 
edema and the nephrotic syndrome has been documented with some P. malariae 
infections [57]. Like that of P. vivax and P. ovale, Chloroquine is also highly effective 
against P. malariae malaria [55].
2.7 Plasmodium knowlesi
P. knowlesi is the only human malaria parasite that can naturally cause malaria in 
humans and other non-human primates (NHP) such as macaque monkeys [59, 60]. 
P. knowlesi is closely related to P. vivax and other Plasmodium species that infect 
non-human primates [61].
The parasite exists in South East Asia [62]. P. knowlesi rarely reported from areas 
outside South East Asia because its vector (the mosquitoes it infects: Anopheles 
hacker and Anopheles latens) are restricted to South East Asia [63, 64]. P. knowlesi 
has three subspecies which includes P. knowlesi edesoni, P. knowlesi sintoni, and  
P. knowlesi arimai [65, 66].
In humans, the parasite can cause both sever and uncomplicated malaria [67]. 
Uncomplicated P. knowlesi malaria is manifested by fever, chills, headaches, joint 
pain, malaise, abdominal pain, diarrhea, and loss of appetite [67]. In contrast to the 
other human malarias, P. knowlesi malaria has daily or quotidian malaria (a fever 
that that spike every 24 hours) [67, 68]. Like that of P. vivax, P. malariae and  
P. ovale, Chloroquine is also highly effective against P. knowlesi malaria [55].
2.8 Zoonotic malaria parasites
In addition to P. knowlesi, other Plasmodium species have also reported to 
cause zoonotic malaria [69, 70]. Macaques has been reported to be reservoir of six 
Plasmodium species, namely P. knowlesi, P. inui, P. cynomolgi, P. coatneyi, P. fieldi 
and P. simiovale in Sarawak in Malaysian Borneo [71]. From these six Plasmodium 
species, P. cynomolgi has been shown to naturally cause human infection [72], and 
P. inui can cause infection in experimental condition [73], suggesting that these 
species might became the next Plasmodium species that may affect human health in 
the future.
Zoonotic malaria has also been reported from other parts of the world. Zoonotic 
malaria that are caused by P. simium [74] and P. brasilianum [75], that naturally 
infect platyrrhine monkeys have been reported in South America. P. simium and  
P. brasilianum are closely related with P. vivax and P. malariae, respectively [76].
3. Antimalarial drugs resistance
There are five groups of antimalarial drugs that are currently used for treatment 
of human malaria, that are classified on basis of their structure and action [77, 78]. 
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The five classes include: - (1). antifolates (pyrimethamine, proguanil, sulfadoxine), 
(2). 4-aminoquinolines (like chloroquine, amodiaquine, hydroxychloroquine, 
and aryl amino alcohols (such as quinine, mefloquine) (3). Endoperoxides (like 
artemisinin and its derivatives), (4) naphthoquinones (like atovaquone), and (5). 
8-aminoquinolines (primaquine, tafenoquine). 4- aminoquinolines, anitifolates, 
naphthoquinones and aryl amino alcohols cause inhibition by detoxification of 
haem, pyrimidine biosynthesis and mitochondrial cytochrome b involved in 
oxidoreduction, respectively. Whereas endoperoxides, such as artemisinin, act 
on multiple cellular processes involving reactive oxygen species in Plasmodium 
cells [78].
One of the major challenges to control malaria is the emergence and spread 
of antimalarial drug-resistant plasmodium parasites [3–5]. The most important 
plasmodium parasites (P. vivax and P. falciparum) have already developed resistance 
against convectional antimalarial drugs such as chloroquine, sulfadoxine-pyrimeth-
amine, atovaquone [79–85]. In response to the evolution of drug resistance strains 
of P. falciparum malaria, since the mid-2000s, artemisinin-based combination 
therapies (ACTs) constitute the standard of care for uncomplicated falciparum 
malaria and are increasingly also taken into consideration for the treatment of non-
falciparum malaria (P. ovale, P. vivax, P. knowlesi and P. malariae) [35].
The artemisinin and its derivatives in ACTs confer rapid and potent effec-
tiveness, whereas their partner drugs are longer-lived antimalarial (such as 
lumefantrine, mefloquine, piperaquine (PPQ ), amodiaquine or sulfadoxine-
pyrimethamine). The reason for use of ACTs is the fact that the artemisinin and its 
derivatives rapidly eliminate the majority of the parasites within days by mecha-
nisms that are distinct from those of the partner drug, which eliminates residual 
parasites over weeks, so that parasites that may develop resistance to the artemisinin 
drug would still be eliminated by the partner drug [86].
There is also widespread resistance of P. vivax to chloroquine and sulfadoxine-
pyrimethamine [84, 85, 87, 88]. Since the early 1990s chloroquine-resistant P. 
vivax (CRPV) has been reported from different parts of the world, mostly from 
Papua New Guinea, the Solomon Islands and Indonesia, Burma (Myanmar), India, 
Vietnam, Turkey, and Central and South America [83]. In Africa, chloroquine 
resistance started in late 1970s, and treatment failure became alarmingly high until 
the introduction of ACT in 2005 [89, 90]. Now, the recommended drugs for the 
treatment of CRPV malaria by the U.S. Centers for Disease Control and Prevention 
(CDC) succeeded by primaquine include; quinine sulfate plus either doxycycline 
or tetracycline; atovaquone-proguanil; and mefloquine [91]. ACTs has been dem-
onstrated to be effective for both chloroquine-resistant and chloroquine-sensitive 
strains of P. vivax malaria. Therefore, ACTs can be now used to treat malaria caused 
by P vivax [92–94]. So far, there are no reports of P. vivax resistance to artemisinins. 
The main drawback of using ACTs for the treatment of P vivax malaria with ACTs 
is that the dormant liver-stage (hypnozoites) are not targeted by the ACTs, and, 
therefore, primaquine is necessarily required in combination with ACTs to prevent 
relapse.
Chloroquine targets the polymerization of free haem (the toxic substance for the 
parasite) within the food vacuole of the parasite. The drug disrupts haemozoin for-
mation so that the parasite dies by the effect of the poisonous haem. The mechanism 
of chloroquine resistance is drug efflux via the P. falciparum chloroquine-resistance 
transporter (encoded by pfcrt) located at the food vacuole. Chloroquine-resistance 
was connected with mutations in pfcrt [95–97].
Sulfadoxine and pyrimethamine inhibit two enzymes of P. falciparum that 
involve in the folate pathway, that are dihydropteroate synthase (PfDhps) and 
dihydrofolate reductase (PfDhfr), respectively. Resistance to these antimalarials 
7
Plasmodium Species and Drug Resistance
DOI: http://dx.doi.org/10.5772/intechopen.98344
arises from multiple mutations in pfdhps and pfdhfr genes [98–101]. In Ethiopia,  
P. falciparum resistance to Sulfadoxine-pyrimethamine (SP) had led to replacement 
of SP with ACT, which is composed of consisted of artemether and lumefantrine 
(Coartem) in 2004 [102]. However, artemisinin resistance in P. falciparum has 
emerged in different parts of the world, especially in Southeast Asia and Africa 
[103–106], which indicates the possibility of the spread of artemisinin resistance to 
all over the world.
4. Conclusions
Malaria remains the major public health problem in tropical and subtropical 
countries of the world. Human malaria is caused by five Plasmodium species, 
namely P. falciparum, P. malariae, P. vivax, P. ovale and P. knowlesi. In addition to 
these parasites, malaria in humans can sometimes arise from zoonotic malaria 
parasites, which includes P. inui, P. cynomolgi, P. coatneyi, P. fieldi, P. simiovale,  
P. simium and P. brasilianum. The plasmodium life cycle involves two hosts (has two 
parts). In the first part, the parasite infects a vertebrate host such as human being 
and in the second part, the plasmodium parasites infect the mosquito vector. The 
malaria parasites differ in their epidemiology, virulence and drug resistance pat-
tern. P. falciparum is the deadliest Plasmodium species that causes human malaria. 
P. falciparum accounted for nearly all malarial deaths (99.7%) in 2018. One of the 
major challenges to control malaria is the emergence and spread of antimalarial 
drug-resistant plasmodium parasites. The most important Plasmodium parasites 
(P. vivax and P. falciparum) have already developed resistance against convectional 
antimalarial drugs such as chloroquine, sulfadoxine-pyrimethamine, atovaquone. 
In response to the evolution of drug resistance Plasmodium parasites, ACTs have 
been used as first line therapy for treatment of uncomplicated falciparum malaria 
since the beginning of 21th century. However, artemisinin resistant P. falciparum 
strains have been recently observed in different parts of the world, which indi-
cates the possibility of the spread of artemisinin resistance to all over the world. 
Therefore, novel antimalarial drugs have to be searched so as to replace the ACTs if 
Plasmodium parasites develop resistance to ACTs in the future.
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